Prevalence and Correlates of DSM-5 Eating Disorders in Nationally Representative Sample of United States Adults
Abstract
Background There exist few population-based data on the prevalence of eating disorders (EDs) and this is especially needed because of changes to diagnoses in the DSM-5. This study aimed to provide lifetime and 12-month prevalence estimates of DSM-5 anorexia nervosa (AN), bulimia nervosa (BN), and binge-eating disorder (BED) from the 2012–2013 National Epidemiologic Survey Alcohol and Related Conditions (NESARC-III). Methods A national sample of 36,306 U.S. adults completed structured diagnostic interviews (AUDADIS-5). Results Prevalence (standard error) estimates of lifetime AN, BN, and BED were 0.80% (0.07%), 0.28% (0.03%), and 0.85% (0.05%). 12-month estimates for AN, BN, and BED were 0.05% (0.02%), 0.14% (0.02%), and 0.44% (0.04%). Adjusting for age, race/ethnicity, education, and income, odds of lifetime and 12-month diagnoses of all three EDs were significantly greater for women than men. Adjusted odds ratios (AORs) of lifetime AN were significantly lower for non-Hispanic Black and Hispanic than for White respondents. AORs of lifetime and 12-month BN did not differ significantly by race/ethnicity. AOR of lifetime BED, but not 12-month, was significantly lower for non-Hispanic Black relative to non-Hispanic White respondents; AORs of BED for Hispanic and non-Hispanic White respondents did not differ significantly. AN, BN, and BED were characterized by significant differences in ages of onset, persistence and duration of episodes, and rates of current obesity and…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.